Quickly find freely available drug and population models in our PBPK model repository.
The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.
You can use a suffix operator (*) as the placeholder for end of a term. The query must start with at least one alphanumeric character before the suffix operator. E.g., Rifam* will get you “Rifampicin” and “Rifampin”. For more advanced searching tips click here.
Brand Name(s) include: Crixivan
Disease: HIV
Drug Class: Protease inhibitor
Date of Review: 2020
Number of Models Reviewed: 1
Number of Models added to the Repository: 1
|
Publication |
Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Unadkat JD. A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction. CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1(9):e3. |
|
Simcyp Version |
V13 |
|
Published Model Application |
Prediction of exposure in pregnancy |
|
Absorption Model |
First Order |
| Volume of Distribution Details |
Full PBPK |
|
Route of Elimination |
|
|
Perpetrator DDI |
|
|
Advantages and Limitations |
|
|
Model Compound Files |
|
Brand Name(s) include: Kaletra (fixed dose combination with low dose ritonavir)
Disease: HIV
Drug Class: Protease inhibitor
Date of Review: 2020
Number of Models Reviewed: 1
Number of Models added to the Repository: 1
|
Publication |
Wagner et al., Physiologically-Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Co-administered with Ritonavir. J Clin Pharmacol. 2017 October ; 57(10): 1295–1304. (FDA model) |
|
Simcyp Version |
V13 |
|
Absorption Model |
First-Order |
| Volume of Distribution Details |
Minimal PBPK |
|
Route of Elimination |
|
|
Perpetrator DDI |
|
|
Advantages and Limitations |
|
|
Model Compound Files |
|
The 4β-hydroxycholesterol (4β-OHC) file is an endogenous biomarker for CYP3A activity mainly measured to evaluated potential CYP3A induction in vivo. 4β-OHC file was developed as a primary metabolite of parent compound, cholesterol.
This document provides:
1. Examples of model performance
2. A summary of the key pharmacokinetic features of cholesterol and 4β-OHC considered within the model
|
20 |